Sugi Predict

Sugi Predict / Compounds / SCHEMBL606594

SCHEMBL606594

SCHEMBL606594

[CH2]CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.48
▸ CYP19A1 P11511 4/20 0.48
▸ PPARG P37231 3/20 0.48
▸ OXER1 Q8TDS5 3/20 0.48
▸ MAPT P10636 3/20 0.48
▸ RXRA P19793 2/20 0.48
▸ FFAR1 O14842 2/20 0.48
▸ PTGS1 P23219 4/20 0.45
▸ F7 P08709 3/20 0.45
▸ F3 P13726 3/20 0.45
▸ PPARA Q07869 3/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ PPARD Q03181 2/20 0.45
▸ ADORA3 P0DMS8 2/20 0.45
▸ NR1I2 O75469 2/20 0.42
▸ PTGS2 P35354 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ PLA2G1B P04054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476325 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL9766332 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL18837286 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL9766336 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL606595 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL5457684 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL1611597 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL1611595 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL3685895 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL5457682 1.00 ALDH1A1 (0.48) ALDH1A1CYP19A1PPARGOXER1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111153827-A Preparation method and application of benzylaminated omega-3 unsaturated fatty acid 广东药科大学 2020-05-15 — — CN claimed
EP-1390378-B1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS TROMMSDORFF ARZNEIMITTEL (DE) 2009-06-17 — — EP claimed
US-7396826-B2 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2008-07-08 — — US claimed
JP-2004531543-A — — 2004-10-14 — — JP claimed
US-20040121979-A1 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2004-06-24 — — US claimed
EP-1390378-A1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS Trommsdorff GmbH & Co. KG Arzneimittel (DE) 2004-02-25 — — EP claimed
WO-2002088159-A1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2002-11-07 — — WO claimed
US-20230293629-A1 METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN BIOMARCK PHARMACEUTICALS LTD (US) 2023-09-21 — — US disclosed
US-20220305078-A1 PEPTIDES AND METHODS OF USE THEREOF IN TREATING UVEITIS PARK STRATEGIC VENTURES LLC 2022-09-29 — — US disclosed
EP-3982928-A1 PEPTIDES AND METHODS OF USE THEREOF IN TREATING UVEITIS Biomarck Pharmaceuticals, Ltd. (US) 2022-04-20 — — EP disclosed
CN-114302706-A Peptides for treating uveitis and methods of use thereof 碧奥马尔克制药有限公司 2022-04-08 — — CN disclosed
EP-3331359-B1 AGRICULTURAL ADJUVANT COMPOSITIONS AND METHODS FOR USING SUCH COMPOSITIONS RHODIA OPERATIONS (FR) 2021-03-17 — — EP disclosed
WO-2020257162-A1 PEPTIDES AND METHODS OF USE THEREOF IN TREATING UVEITIS BIOMARCK PHARMACEUTICALS LTD. (US) 2020-12-24 — — WO disclosed
EP-1666092-A2 Drug combination comprising a fatty acid and a uridine compound. Trommsdorff GmbH & Co.KG Arzneimittel (DE) 2006-06-07 — — EP disclosed
US-20050065110-A1 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO., KG ARZNEIMITTEL 2005-03-24 — — US disclosed
US-20050043269-A1 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL 2005-02-24 — — US disclosed
US-20050043394-A1 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL 2005-02-24 — — US disclosed
US-20040121979-A1 Pharmaceutically active uridine esters TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2004-06-24 — — US disclosed
EP-1390378-A1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS Trommsdorff GmbH & Co. KG Arzneimittel (DE) 2004-02-25 — — EP disclosed
WO-2002088159-A1 PHARMACEUTICALLY ACTIVE URIDINE ESTERS TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) 2002-11-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043394-A1 Pharmaceutically active uridine esters UMPS, UGDH, FFAR3 ALDH1A1 342/4885CYP19A1 1191/4885PPARG 278/4885
US-20040121979-A1 Pharmaceutically active uridine esters UMPS, UGDH, FFAR1 ALDH1A1 142/4885CYP19A1 958/4885PPARG 287/4885
US-20050043269-A1 Pharmaceutically active uridine esters UMPS, UGDH, FFAR3 ALDH1A1 342/4885CYP19A1 1191/4885PPARG 278/4885
US-20050065110-A1 Pharmaceutically active uridine esters UMPS, UGDH, FFAR3 ALDH1A1 342/4885CYP19A1 1191/4885PPARG 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.